Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
Heerspink HJL, Furtado RHM, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, Gasparyan SB, Tang F, Windsor SL, de Souza-Dantas VC, Del Sueldo M, Frankel R, Javaheri A, Maldonado RA, Morse C, Mota-Gomes M, Shemin D, Silva OL Jr, Tognon AP, Twahirwa M, Buenconsejo J, Esterline R, Oscarsson J, Ambery P, Langkilde AM, Kosiborod MN. Heerspink HJL, et al. Among authors: gasparyan sb. Clin J Am Soc Nephrol. 2022 May;17(5):643-654. doi: 10.2215/CJN.14231021. Epub 2022 Apr 28. Clin J Am Soc Nephrol. 2022. PMID: 35483733 Free PMC article. Clinical Trial.
Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review.
Little DJ, Gasparyan SB, Schloemer P, Jongs N, Brinker M, Karpefors M, Tasto C, Rethemeier N, Frison L, Nkulikiyinka R, Rossert J, Heerspink HJL. Little DJ, et al. Among authors: gasparyan sb. J Am Soc Nephrol. 2023 Dec 1;34(12):1928-1935. doi: 10.1681/ASN.0000000000000244. Epub 2023 Oct 9. J Am Soc Nephrol. 2023. PMID: 37807165 Free PMC article. Review.
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
Heerspink HJL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB. Heerspink HJL, et al. Among authors: gasparyan sb. J Am Soc Nephrol. 2023 Dec 1;34(12):2025-2038. doi: 10.1681/ASN.0000000000000243. Epub 2023 Oct 24. J Am Soc Nephrol. 2023. PMID: 37872654 Free PMC article.
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Kosiborod M, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Javaheri A, Ambery P, Gasparyan SB, Buenconsejo J, Sjöström CD, Langkilde AM, Oscarsson J, Esterline R. Kosiborod M, et al. Among authors: gasparyan sb. Diabetes Obes Metab. 2021 Apr;23(4):886-896. doi: 10.1111/dom.14296. Epub 2021 Jan 19. Diabetes Obes Metab. 2021. PMID: 33319454 Free PMC article.
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.
Kondo T, Gasparyan SB, Jhund PS, Bengtsson O, Claggett BL, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Ponikowski P, Sabatine MS, Shah SJ, Sjostrand M, Wilderang U, Vaduganathan M, Solomon SD, McMurray JJV. Kondo T, et al. Among authors: gasparyan sb. NEJM Evid. 2023 Nov;2(11):EVIDoa2300042. doi: 10.1056/EVIDoa2300042. Epub 2023 Oct 24. NEJM Evid. 2023. PMID: 38320525
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
Kondo T, Mogensen UM, Talebi A, Gasparyan SB, Campbell RT, Docherty KF, de Boer RA, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon SD, Jhund PS, McMurray JJV. Kondo T, et al. Among authors: gasparyan sb. J Am Coll Cardiol. 2024 May 21;83(20):1973-1986. doi: 10.1016/j.jacc.2024.03.385. Epub 2024 Mar 25. J Am Coll Cardiol. 2024. PMID: 38537918 Free article. Clinical Trial.
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.
Lam CSP, Køber L, Kuwahara K, Lund LH, Mark PB, Mellbin LG, Schou M, Ely Pizzato P, Gabrielsen A, Gasparyan SB, Ghiretti A, Hartleib-Geschwindner J, Housler GJ, Fanti P, Leonsson-Zachrisson M, McMurray JJV, Solomon SD; MIRACLE Study Investigators. Lam CSP, et al. Among authors: gasparyan sb. Eur J Heart Fail. 2024 Aug;26(8):1727-1735. doi: 10.1002/ejhf.3294. Epub 2024 May 23. Eur J Heart Fail. 2024. PMID: 38783712 Clinical Trial.
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF, Aboudara M, Hoffmann Filho CR, Feitosa ADM, Fonseca A, Garla V, Gordon RA, Javaheri A, Jaeger CP, Leaes PE, Nassif M, Pursley M, Silveira FS, Barroso WKS, Lazcano Soto JR, Nigro Maia L, Berwanger O. Kosiborod MN, et al. Among authors: gasparyan sb. Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34302745 Free PMC article. Clinical Trial.
20 results